GSK to Acquire Nuvalent in Largest Deal in Over a Decade – Merger Arbitrage Mondays
Nuvalent, Inc. (NUVL): $123.25 Market Cap: $9.07 B Deal Value: $9.4 B British pharma giant GSK plc (GSK) entered into a definitive merger agreement on June 9, 2026, to acquire…
Written byAsif SuriaSource: InsideArbitrage
Nuvalent, Inc. (NUVL): $123.25 Market Cap: $9.07 B Deal Value: $9.4 B British pharma giant GSK plc (GSK) entered into a definitive merger agreement on June 9, 2026, to acquire oncology drug developer Nuvalent in a cash deal valued at $9.4 billion, its largest in over a decade. GSK will commence a tender offer within 10 business days